tbuckley/cabot-search huggingface dataset:
Myocardial Blood Flow Response to Pacing Tachycardia and to Dipyridamole Infusion in Patients With Dilated Cardiomyopathy Without Overt Heart Failure
Authors: DaniloNeglia, OberdanParodi, MichelaGallopin, GianmarioSambuceti, AssueroGiorgetti, LorenzaPratali, PieroSalvadori, ClaudioMichelassi, MaurizioLunardi, GualtieroPelosi, MarioMarzilli, AntonioL’Abbate
Journal: Circulation (1995)

Background Myocardial blood flow (MBF) impairment has been documented in advanced dilated cardiomyopathy (DCM) in which hemodynamic factors, secondary to severe ventricular dysfunction, may limit myocardial perfusion. To assess whether MBF impairment in DCM may also be present independent of hemodynamic factors, the present study was designed to quantify myocardial perfusion in patients with mild disease without overt heart failure. Methods and Results Absolute regional MBF (milliliters per minute per gram) was measured by positron emission tomography and 13N-ammonia in resting conditions, during pacing-induced tachycardia, and after dipyridamole infusion (0.56 mg/kg over 4 minutes) in 22 DCM patients and in 13 healthy subjects. Patients were in New York Heart Association functional class I-II and showed depressed left ventricular (LV) ejection fraction by radionuclide angiography (35±8%; range, 21% to 48%), normal coronary angiography, and normal or moderately increased LV end-diastolic pressure (9.2±5.5...
Immune Thrombocytopenia—A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials—In Reply
Authors: Yucai Wang, Fang Yang, Michael L. Wang
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis
Authors: Hideaki Tsuji, Ran Nakashima, Yuji Hosono, Yoshitaka Imura, Masato Yagita, Hajime Yoshifuji, Shintaro Hirata, Takaki Nojima, Eiji Sugiyama, Kazuhiro Hatta, Yoshio Taguchi, Masaki Katayama, Kiminobu Tanizawa, Tomohiro Handa, Ryuji Uozumi, Shuji Akizuki, Kosaku Murakami, Motomu Hashimoto, Masao Tanaka, Koichiro Ohmura, Tsuneyo Mimori
Journal: Arthritis & Rheumatology (2019)

Objective Interstitial lung disease ( ILD ) accompanied by anti–melanoma differentiation–associated gene 5 (anti– MDA ‐5)–positive dermatomyositis ( DM ) is often rapidly progressive and associated with poor prognosis. Because there is no established treatment, we undertook this study to prospectively evaluate the efficacy and safety of a combined immunosuppressive regimen for anti– MDA ‐5–positive DM patients with ILD . Methods Adult Japanese patients with new‐onset anti– MDA ‐5–positive DM with ILD (n = 29) were enrolled at multiple study centers from 2014 to 2017. They were treated with a regimen of high‐dose glucocorticoids ( GC s), tacrolimus, and intravenous cyclophosphamide ( IV CYC ). Plasmapheresis was used if a patient's condition worsened after the regimen started. The primary end point was 6‐month survival, which was compared between this group of patients and a historical control group (n = 15) consisting of anti– MDA ‐5–positive DM patients with ILD who received step‐up treatment (high‐dose GC and stepwise addition of immunosuppressant). Secondary end points were 12‐month survival rate, adverse events, and changes in laboratory data. Results The combined immunosuppressive regimen group showed significantly higher 6‐month survival rates than the step‐up treatment group (89% versus 33%; P &lt; 0.0001). Over a period of 52 weeks, improvements in anti– MDA ‐5 titers, serum ferritin levels, vital capacity, and chest high‐resolution computed tomography scores were observed. The combined immunosuppressive regimen group received IV CYC nearly 20 days earlier with shorter intervals and tended to receive plasmapheresis more often than patients undergoing step‐up treatment. Cytomegalovirus reactivation was frequently observed over 52 weeks. Conclusion A combined immunosuppressive regimen is effective for anti– MDA ‐5–positive DM patients with ILD . Plasmapheresis can be used for additional effect in intractable disease. Patients should be carefully monitored for opportunistic infections during treatment.
Targeting Histone Deacetylase 6 Reprograms Interleukin‐17‐Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma
Authors: Weinan Qiu, Bin Wang, Yanan Gao, Yuan Tian, Meijie Tian, Yuanying Chen, Li Xu, Tso‐Pang Yao, Peng Li, Pengyuan Yang
Journal: Hepatology (2019)

Background and Aims Hepatocellular carcinoma (HCC) is often accompanied by resistance to immunotherapies despite the presence of tumor‐infiltrating lymphocytes. We report that histone deacetylase 6 (HDAC6) represses interleukin‐17 (IL‐17)–producing helper T (T H 17) cell pathogenicity and the antitumor immune response, dependent on its deacetylase activity. Approach and Results Adoptive transfer of HDAC6‐deficient T H 17 cells impedes HCC growth, dependent on elevated IL‐17A, by enhancing the production of antitumor cytokine and cluster of differentiation 8–positive (CD8+) T cell–mediated antitumor responses. Intriguingly, HDAC6‐depleted T cells trigger programmed cell death protein 1 (PD‐1)–PD‐1 ligand 1 expression to achieve a strong synergistic effect to sensitize advanced HCC to an immune checkpoint blocker, while blockade of IL‐17A partially suppresses it. Mechanistically, HDAC6 limits T H 17 pathogenicity and the antitumor effect through regulating forkhead box protein O1 (FoxO1). HDAC6 binds and deacetylates cytosolic FoxO1 at K242, which is required for its nuclear translocation and stabilization to repress retinoic acid–related orphan receptor gamma (RoRγt), the transcription factor of T H 17 cell. This regulation of HDAC6 for murine and human T H 17 cell is highly conserved. Conclusions These results demonstrate that targeting the cytosolic HDAC6–FoxO1 axis reprograms the pathogenicity and antitumor response of T H 17 cells in HCC, with a pathogenicity‐driven responsiveness to facilitate immunotherapies
Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study
Authors: Olga Blau, Irina Martynkevich, Franziska Behrenbeck, Claudia D. Baldus, Ekaterina Motiko, Sergei Voloshin, Antonio Pezzutto, Bernd Dorken, Igor Wolfgang Blau
Journal: Blood (2017)
Injuries in elite women’s ski jumping: surveillance through the 2017–18 FIS World Cup season
Authors: Oleane Marthea Rebne Stenseth, Sindre Fløtlien Barli, Richard Kyle Martin, Lars Engebretsen
Journal: British Journal of Sports Medicine (2019)

Objectives To describe the incidence, type, aetiology and severity of injuries sustained by the International Ski Federation World Cup level female ski jumpers during the 2017–18 season. Design Prospective cohort study. Methods Sixty-seven female ski jump athletes from 16 countries were followed throughout the 17-week winter season. Preseason baseline demographic data and injury history were recorded via questionnaire. Prospective biweekly reports and retrospective end-of-season interviews provided data on all injuries requiring medical attention. Results Seventeen injuries were recorded, corresponding to an incidence of 25.4 injuries/100 athletes/season. The incidence of time-loss and severe injuries were found to be 17.9 and 4.5, respectively. The knee was the most common site of injury (4/17; 23.5%). Fourteen injuries occurred on the ski jump hill and crash-landing was the most common mechanism of injury (10/14; 71%). Eighty-five per cent of all moderate and severe injuries occurred in snow or windy conditions. Length of jumps resulting in injury averaged 83.7% (95% CI 72.9% to 94.4%) of hill size. Moderate injuries causing 8–28 days absence from training activities were most common (7/17; 41%) and there were three severe injuries necessitating &gt;4 weeks absence. Conclusion Injuries among elite female ski jumpers are common and the majority are acute, resulting in time loss from training and competition. The knee was the most common site of injury and poor weather conditions may be a risk factor. Future studies are needed to identify risk factors for injury and to guide injury prevention initiatives.
Determinants of Exercise Capacity and Myocardial Perfusion Reserve in Asymptomatic Patients With Aortic Stenosis
Authors: Anvesha Singh, Michael Jerosch-Herold, Soliana Bekele, Anna-Marie Marsh, John McAdam, John P. Greenwood, Dana K. Dawson, Chim C. Lang, Colin Berry, Ruiqi Zhang, Mini Pakkal, Gerry P. McCann
Journal: JACC. Cardiovascular imaging (2019)
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
Authors: Maria Fleseriu, Rosario Pivonello, Atanaska Elenkova, Roberto Salvatori, Richard J Auchus, Richard A Feelders, Eliza B Geer, Yona Greenman, Przemyslaw Witek, Fredric Cohen, Beverly M K Biller
Journal: The Lancet Diabetes & Endocrinology (2019)
Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study
Authors: Alexandre Loupy, Olivier Aubert, Babak J Orandi, Maarten Naesens, Yassine Bouatou, Marc Raynaud, Gillian Divard, Annette M Jackson, Denis Viglietti, Magali Giral, Nassim Kamar, Olivier Thaunat, Emmanuel Morelon, Michel Delahousse, Dirk Kuypers, Alexandre Hertig, Eric Rondeau, Elodie Bailly, Farsad Eskandary, Georg Böhmig, Gaurav Gupta, Denis Glotz, Christophe Legendre, Robert A Montgomery, Mark D Stegall, Jean-Philippe Empana, Xavier Jouven, Dorry L Segev, Carmen Lefaucheur
Journal: BMJ (2019)

Abstract Objective To develop and validate an integrative system to predict long term kidney allograft failure. Design International cohort study. Setting Three cohorts including kidney transplant recipients from 10 academic medical centres from Europe and the United States. Participants Derivation cohort: 4000 consecutive kidney recipients prospectively recruited in four French centres between 2005 and 2014. Validation cohorts: 2129 kidney recipients from three centres in Europe and 1428 from three centres in North America, recruited between 2002 and 2014. Additional validation in three randomised controlled trials ( NCT01079143 , EudraCT 2007-003213-13, and NCT01873157 ). Main outcome measure Allograft failure (return to dialysis or pre-emptive retransplantation). 32 candidate prognostic factors for kidney allograft survival were assessed. Results Among the 7557 kidney transplant recipients included, 1067 (14.1%) allografts failed after a median post-transplant follow-up time of 7.12 (interquartile range 3.51-8.77) years. In the derivation cohort, eight functional, histological, and immunological prognostic factors were independently associated with allograft failure and were then combined into a risk prediction score (iBox). This score showed accurate calibration and discrimination (C index 0.81, 95% confidence interval 0.79 to 0.83). The performance of the iBox was also confirmed in the validation cohorts from Europe (C index 0.81, 0.78 to 0.84) and the US (0.80, 0.76 to 0.84). The iBox system showed accuracy when assessed at different times of evaluation post-transplant, was validated in different clinical scenarios including type of immunosuppressive regimen used and response to rejection therapy, and outperformed previous risk prediction scores as well as a risk score based solely on functional parameters including estimated glomerular filtration rate and proteinuria. Finally, the accuracy of the iBox risk score in predicting long term allograft loss was confirmed in the three randomised controlled trials. Conclusion An integrative, accurate, and readily implementable risk prediction score for kidney allograft failure has been developed, which shows generalisability across centres worldwide and common clinical scenarios. The iBox risk prediction score may help to guide monitoring of patients and further improve the design and development of a valid and early surrogate endpoint for clinical trials. Trial registration Clinicaltrials.gov NCT03474003 .
The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality
Authors: Chaofan Li, Bibo Zhu, Young Min Son, Zheng Wang, Li Jiang, Min Xiang, Zhenqing Ye, Kathryn E. Beckermann, Yue Wu, James W. Jenkins, Peter J. Siska, Benjamin G. Vincent, Y.S. Prakash, Tobias Peikert, Brian T. Edelson, Reshma Taneja, Mark H. Kaplan, Jeffrey C. Rathmell, Haidong Dong, Taro Hitosugi, Jie Sun
Journal: Immunity (2019)
Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease
Authors: Brent P. Forester, Regan E. Patrick, David G. Harper
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Immunohematology and Transfusion Support of a Patient with Acute Myeloid Leukemia and an Anti-Vel
Authors: Jennifer J. O'Brien, Najeebah A. Bade, Agnes Hallie Lee-Stroka, Sakhone B. Learn, Sandra Nance, Christine A. Tremblay, Heather L. McGann, Patricia A. R. Brunker, Nancy M. Hardy, Maria R. Baer, Magali J. Fontaine
Journal: Blood (2017)
Is Ophthalmic Therapy Often Overlooked in Hospital Wards?
Authors: N H V Chong, J R Murdoch
Journal: Journal of the Royal Society of Medicine (1993)

In a prospective study regarding the accuracy of ophthalmic drugs prescriptions of 55 inpatients in two general teaching hospitals, it was found that: only 27.3% of these patients had their ocular therapy correctly prescribed; 38.2% had their eye medications incorrectly prescribed; and 34.5% had no ophthalmic drugs prescribed. The authors conclude that more care during case history taking could prevent such errors.
New Indications for Lyme Disease Tests
Authors: Feyza Sancar
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Absolute Stress Myocardial Blood Flow After Coronary CT Angiography Guides Referral to Invasive Angiography
Authors: Iida Stenström, Teemu Maaniitty, Valtteri Uusitalo, Heikki Ukkonen, Sami Kajander, Maija Mäki, Wail Nammas, Jeroen J. Bax, Juhani Knuuti, Antti Saraste
Journal: JACC. Cardiovascular imaging (2019)
Effect modifiers of lung function and daily air pollutant variability in a panel of schoolchildren
Authors: Graciela Mentz, Thomas G Robins, Stuart Batterman, Rajen N Naidoo
Journal: Thorax (2019)

Background Acute pollutant-related lung function changes among children varies across pollutants and lag periods. We examined whether short-term air pollutant fluctuations were related to daily lung function among a panel of children and whether these effects are modified by airway hyperresponsiveness, location and asthma severity. Methods Students from randomly selected grade 4 classrooms at seven primary schools in Durban, participated, together with asthmatic children from grades 3–6 (n=423). The schools were from high pollutant exposed communities (south) and compared with schools from communities with lower levels of pollution (north), with similar socioeconomic profiles. Interviews, spirometry and methacholine challenge testing were conducted. Bihourly lung function measurements were performed over a 3-week period in four phases. During all schooldays, students blew into their personal digital monitors every 1.5–2 hours. Nitrogen dioxide (NO 2 ), nitrogen oxide (NO), sulphur dioxide and particulate matter (&lt;10 μm diameter) (PM 10 ) were measured at each school. Generalised estimating equations assessed lag effects, using single-pollutant (single or distributed lags) models. Results FEV 1 declines ranged from 13 to 18 mL per unit increase in IQR for NO and 14–23 mL for NO 2 . Among the 5-day average models, a 20 mL and 30 mL greater drop in FEV 1 per IQR for NO 2 and NO, respectively, among those with airway hyperresponsiveness compared with those without. Effects were seen among those with normal airways. Conclusions This first panel study in sub-Saharan Africa, showed significant declines in lung function, in response to NO and NO 2 with effects modified by airway hyperresponsiveness or persistent asthma.
Erratum: Correction: Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil (PLoS medicine (2019) 16 1 (e1002737))
Authors: Tarub S. Mabud, Maria de Lourdes Delgado Alves, Albert I. Ko, Sanjay Basu, Katharine S. Walter, Ted Cohen, Barun Mathema, Caroline Colijn, Everton Lemos, Julio Croda, Jason R. Andrews
Journal: PLoS Medicine (2019)
Erratum for the Research Article: “Genomic profiling of ER <sup>+</sup> breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance” by J. M. Giltnane, K. E. Hutchinson, T. P. Stricker, L. Formisano, C. D. Young, M. V. Estrada, M. J. Nixon, L. Du, V. Sanchez, P. G. Ericsson, M. G. Kuba, M. E. Sanders, X. J. Mu, E. M. Van Allen, N. Wagle, I. A. Mayer, V. Abramson, H. Gόmez, M. Rizzo, W. Toy, S. Chandarlapaty, E. L. Mayer, J. Christiansen, D. …
Journal: Science Translational Medicine (2019)
Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning
Authors: Rainer König, Xueqi Cao, Marcus Oswald, Christina Forstner, Gernot Rohde, Jan Rupp, Martin Witzenrath, Tobias Welte, Martin Kolditz, Mathias Pletz
Journal: European Respiratory Journal (2019)

The role of macrolide/β-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on aetiological and clinical parameters, which are available ex ante to support a personalised decision for or against macrolides for the best clinical outcome of the individual patient.We employed machine learning in a cross-validation scheme based on a well-balanced selection of 4898 patients after propensity score matching to data available on admission of 6440 hospitalised patients with moderate severity (non-intensive care unit patients) from the observational, prospective, multinational CAPNETZ study. We aimed to improve the primary outcome of 180-day survival.We found a simple decision tree of patient characteristics comprising chronic cardiovascular and chronic respiratory comorbidities as well as leukocyte counts in the respiratory secretion at enrolment. Specifically, we found that patients without cardiovascular or patients with respiratory comorbidities and high leukocyte counts in the respiratory secretion benefit from macrolide treatment. Patients identified to be treated in compliance with our treatment suggestion had a lower mortality of 27% (OR 1.83, 95% CI 1.48-2.27; p<0.001) compared to the observed standard of care.Stratifying macrolide treatment in patients following a simple treatment rule may lead to considerably reduced mortality in CAP. A future randomised controlled trial confirming our result is necessary before implementing this rule into the clinical routine.